Select DBS contacts using LFP

Trial ID
NCT07485621
Official Title
Assessing the Relation Between Subcortical LFPs and DBS Parameter Selection in Parkinson's Disease - a Prospective Study
Goal
Select DBS contacts using LFP
Status
RECRUITING
Sponsor
Loes Laurijssen
Study Type
OBSERVATIONAL
Enrollment
40 participants
Conditions
Parkinson's Disease (PD)

Plain-Language Summary

It aims to find out whether tiny electrical rhythms from deep brain areas, called local field potentials or LFPs, can help clinicians choose DBS settings that control tremor, slowness, and stiffness while reducing side effects. Researchers will record LFPs from the implanted DBS electrodes during routine programming and look for patterns, like elevated beta-band activity that links to rigidity and bradykinesia, that predict which contacts, voltages, or frequencies work best. Because LFPs change with levodopa and motor state, the hope is that these signals could help personalize stimulation to work alongside medications, while participants receive standard clinical programming. Adults 18 and older with idiopathic Parkinson disease who are approved for DBS to treat refractory motor symptoms and who understand Dutch or French are eligible; about 40 people will be enrolled.

Locations

  • University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium

Frequently Asked Questions

What is this trial testing?
This trial is studying an experimental treatment. It aims to find out whether tiny electrical rhythms from deep brain areas, called local field potentials or LFPs, can help clinicians choose DBS settings that control tremor, slowness, and stiffness while reducing side effects. Researchers will record LFPs from the implanted DBS electrodes during routine programming and look for patterns, like elevated beta-band activity that links to rigidity and bradykinesia, that predict which contacts, voltages, or frequencies work best. Because LFPs change with levodopa and motor state, the hope is that these signals could help personalize stimulation to work alongside medications, while participants receive standard clinical programming. Adults 18 and older with idiopathic Parkinson disease who are approved for DBS to treat refractory motor symptoms and who understand Dutch or French are eligible; about 40 people will be enrolled.
Who can participate?
Participants must be at least 18 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 3 years.

View on ClinicalTrials.gov